55 results about "Oxalomalic acid" patented technology

The invention relates to a preparation method of a lithium difluoro-bis (oxalate) phosphate concentrated solution, the lithium difluoro-bis (oxalate) phosphate concentrated solution is composed of lithium difluoro-bis (oxalate) phosphate and an aprotic solvent, the aprotic solvent comprises any one or a combination of at least two of diethyl carbonate, ethyl methyl carbonate, ethylene carbonate or propylene carbonate, the concentration of the lithium difluoro-bis (oxalate) phosphate in the lithium difluoro-bis (oxalate) phosphate concentrated solution is 10-35 wt%. The lithium difluoro bis (oxalate) phosphate concentrate provided by the invention exists in a non-proton electrolyte state, so that an evaporative crystallization process is omitted, and the production cost is reduced; the product transportation cost can be reduced through pipeline transportation; and compared with a lithium phosphate solid difluoro bis (oxalate), the process of re-dissolution during use is omitted, the risk of impurity introduction is avoided, and the use cost is reduced.

Electrolyte solution comprising a first lithium salt, a second lithium salt and a first additive, wherein the first lithium salt comprises at least lithium bis(fluorosulfonyl)imide and the second lithium salt is selected from the group consisting of lithium difluoro(oxalato)borate, lithium difluorobis(oxalato)phosphate and a combination thereof; and the first additive is methylenemethanedisulfonate.

The utility model relates to the field of a dimethyl oxalate synthesis process, in particular to a nitric acid feeding line and dimethyl oxalate production equipment, an original nitric acid liquid inlet subline is cancelled, and a nitric acid boundary valve is arranged at the output end of a nitric acid feeding system to control the flow of nitric acid entering a specific area or system, so that the nitric acid is ensured to flow in a specified range; it is ensured that nitric acid can stably and continuously enter the next link through a nitric acid feeding valve; through the arrangement of the nitric acid drainage regulating valve and the check valve behind the nitric acid feeding valve, after nitric acid supplementing is stopped, the nitric acid in the pipeline is released through the nitric acid drainage regulating valve, nitric acid accumulated liquid stored in the pipeline is avoided, and therefore the situation that the nitric acid flows backwards and reacts with liquid stored in the pipeline is doubly avoided; and the safety of the pipeline is further improved. The problem that the accident risk is high due to the fact that nitric acid feed of an existing nitric acid reduction tower accumulates in a pipeline and reacts with alcohol-containing liquid of a methyl nitrite regeneration tower reversely into the nitric acid pipeline is solved.

The invention relates to a synthesis method of dimethyl oxalate, and mainly solves the technical problems of high reaction hot spot temperature, poor dimethyl oxalate selectivity and low space time yield in the prior art. According to the technical scheme, carbon monoxide, nitrogen and methyl nitrite (MN) are used as raw materials, and under the conditions that the inlet temperature is 70-100 DEG C, the volume space velocity is 1000-5000h <-1 >, the CO molar concentration is 10-40%, the CO / MN molar ratio is 1.0-3.0 and the reaction pressure is 0.05-2.0 Mpa, the raw materials pass through a Pd catalyst diluted by small balls with low specific surface area, large aperture and low acid content, the hot-spot temperature of a bed is lower than 125 DEG C, and the reaction is carried out for 1-2 hours, so that the methyl nitrite (MN) is obtained. According to the technical scheme, the problems are well solved, the selectivity of the dimethyl oxalate is larger than 98% in the long-time operation process, the space time yield of the dimethyl oxalate is larger than 750 g / (L.h), and the method can be used for industrial production of synthesizing the dimethyl oxalate through oxidative coupling of carbon monoxide.

The invention discloses a battery monomer, an isolating membrane, a preparation method of the isolating membrane, a battery device and a power utilization device, the battery monomer comprises the isolating membrane and electrolyte, and the isolating membrane comprises a porous base membrane; the coating is arranged on at least one side of the porous base membrane and comprises a polymer additive, and the polymer additive comprises a first functional group and a second functional group; the first functional group comprises one or more of bis (fluorosulfonyl) imino group, bis (trifluoromethyl) sulfonyl imino group, trifluoroboric acid group, hexafluorophosphoric acid group, sulfonic acid group, hexafluoroarsenate group, trifluoromethanesulfonic acid group, difluorophosphoric acid group, bis (oxalato) boric acid group, difluoro (oxalato) boric acid group, difluoro (oxalato) phosphoric acid group, tetrafluoro (oxalato) phosphoric acid group and imidazolyl; the second functional group comprises one or more of quaternary ammonium ions, pyrrolidinyl, pyrrolyl, piperidinyl, pyridyl and imidazolyl. The battery monomer has good dynamic performance; the invention provides the isolating membrane for realizing the beneficial effects of the battery monomer, the preparation method of the isolating membrane, the battery device and the power utilization device.

The present invention relates to a process for the production of a polyester (co)polymer, comprising the steps of a) adding a dialkyl oxalate ester to a starting polyester (co)polymer at least comprising carboxylic acid derived monomer units and 1,2-diol derived alcohol end groups, 5 wherein the alkyl group in the dialkyl oxalate ester is an aliphatic alkyl group wherein the carbon in the alkyl group that is attached to the oxalate is a primary carbon; and b) in case the temperature is not already higher than 220 °C, elevating the temperature of the mixture resulting from step (a) to at least 220 °C, and reducing the pressure, for a period of time sufficient to obtain a polyester (co)polymer product having a higher molecular weight than that of the starting 10 polyester (co)polymer, wherein the amount of oxalate units that remain in the (co)polymer is less than the amount added in the form of the dialkyl oxalate ester.

An electrolyte additive, a preparation method therefor, and an application thereof. The electrolyte additive comprises a halogen-substituted tris(oxalato)diborate, the halogen-substituted tris(oxalato)diborate having a structure as shown in formula I, where R1 and R2 are each independently selected from one of the halogens, and M+ are selected from one of the alkali metal ions. The halogen-substituted tris(oxalato)diborate has relatively good chemical stability and electrochemical stability, is used in an electrolyte of a secondary battery, and improves the thermal stability effect of a product. In addition, since the halogen-substituted tris(oxalato)diborate has more oxalate functional groups, the ion concentration in the electrolyte can be well adjusted, which can effectively improve the conductivity of an electrolyte, such that the voltage of a battery can be more easily maintained within a suitable range.

The utility model discloses a lithium difluoro (oxalato) borate synthesis device which comprises a synthesis kettle which is respectively connected with an organic solvent feeding pipeline, a solid lithium oxalate feeder, at least one feed gas boron trifluoride feeding pipeline and a synthesis liquid discharging pipeline, according to the device disclosed by the utility model, additives are not required to be added, dangerous hydrogen fluoride materials are not required to be used, boron trifluoride raw material gas is used, and continuous pipeline conveying is easier to control, so that the synthesis process becomes simple and easy, other impurities are not introduced, and the operation risk is greatly reduced.

The application provides a folic acid-containing composition and application, an orally disintegrating tablet and a preparation method. The folic acid-containing composition comprises folic acid raw materials, escitalopram oxalate and memantine hydrochloride. The weight ratio of the folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride is (0.4-5):(10-20):(5-30). The folic acid raw materials comprise one or more of folic acid and derivatives thereof. The folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride are used in a specific proportion, can be synergistic, can effectively treat post-stroke central neuropathic pain with depression, and can prevent recurrence of stroke, and are beneficial to post-stroke rehabilitation.

The invention discloses a preparation method of lithium difluoro (oxalato) borate. Lithium hydroxide, trimethyl borate, dimethyl oxalate and anhydrous ammonium bifluoride steam are used as raw materials to react in an ionic liquid medium. The method adopts a plasma activation technology, can be efficiently carried out in a low-temperature environment without traditional heating, not only shortens the reaction period, but also can inhibit fluorine source decomposition, oxalate hydrolysis and other side reactions, improves the selectivity of a target product, and uses the ionic liquid as a reaction medium, and the high polarity and low volatility of the ionic liquid can ensure the uniform dispersion of raw materials. Meanwhile, supercritical carbon dioxide extraction replaces traditional recrystallization, one-step purification is achieved by means of the selective dissolution characteristic of supercritical carbon dioxide extraction, the process steps are simplified, and solvent residues are reduced.

The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.

The invention relates to an oxalate hydrogenation catalyst carrier, a catalyst and a preparation method, and the method comprises the following steps: enabling gasified fly ash to electrostatically adsorb a cationic surfactant type pore-foaming agent, hydrolyzing tetraethyl orthosilicate under the action of the cationic surfactant and ammonia water, and forming a silicon dioxide shell layer on the surface of the gasified fly ash, after the cationic surface active agent is completely decomposed through calcination, a porous structure is formed on a silicon dioxide shell layer of the gasified fly ash to serve as an active center load; according to the method, the defect that strong acid / strong base is adopted in the traditional technology can be effectively avoided, meanwhile, compared with KCC-1, MCM-41, SBA-15 and other silicon dioxide carriers, the purpose of greatly reducing the carrier cost can be achieved on the premise that the conversion rate of dimethyl oxalate is as high as 98.61% through a catalyst prepared based on the carrier dipping active metal, and in addition, the method has the advantages that the cost of the carrier is greatly reduced. The gasified fly ash which is used as solid waste is also developed with high value.

The present invention provides an immediate release oral pharmaceutical composition comprising, by weight, greater than or equal to 60.1% of citalopram oxalate or escalopram oxalate or greater than or equal to 25.1% of citalopram oxalate or escalopram oxalate having a median diameter greater than 40 [mu] m, and 0% to 74.9% of an additional pharmaceutical excipient.

The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.

The invention provides a desulfurizing agent and application thereof. The desulfurizing agent comprises a first complexing agent-iron complex, a second complexing agent-iron complex and ionic liquid, the first complexing agent is EDTA (Ethylene Diamine Tetraacetic Acid); the second complexing agent is selected from at least one of HEDTA, citric acid, salicylic acid, sulfosalicylic acid and tartaric acid; the ionic liquid comprises at least one of substituted or unsubstituted imidazole cations, pyridine cations, thiazole cations, piperidine cations, pyrazole cations and oxazole cations; and further comprises at least one of oxalate anions, acetate anions, salicylate anions, sulfosalicylate anions, citrate anions and tartrate anions. The desulfurizer has the advantage of high total sulfur removal rate.

The present invention relates to the field of fine chemicals, and specifically relates to a preparation method of sodium bis(oxalato)borate; the present invention uses a sodium source, boric acid, and oxalic acid as raw materials, and synthesizes sodium bis(oxalato)borate by a solid-phase method, and uses a method combining antisolvent crystallization and thermal crystallization to purify sodium bis(oxalato)borate. The present invention has the advantages of high yield and rapid purification process; the present invention uses a solid-phase synthesis method combined with a purification method, which can greatly shorten the synthesis and purification time; the sodium bis(oxalato)borate prepared by the present invention has high purity, high yield, and high conductivity, and can be used as an electrolyte for batteries; the electrolyte prepared from the sodium bis(oxalato)borate prepared by the present invention has better cycling performance at low rates than commercial electrolytes.

The application discloses a preparation method, a catalytic material and application of an oxalate-based nickel-iron MOF doped carbon nanotube catalytic material. The preparation method comprises the following steps: dispersing nickel nitrate hexahydrate, potassium trioxalate ferrate and carbon nanotubes into a methanol solution, stirring at room temperature after ultrasonic treatment to obtain a mixed solution with precipitates, centrifuging the obtained mixed solution, washing with methanol, and vacuum drying to obtain the oxalate-based nickel-iron MOF doped carbon nanotube catalytic material. The oxalate-based coordination is utilized to synthesize the oxalate-based bridged Ni-Fe bimetallic coordination polymer by one-step synthesis. The oxalate-based oxygen bridge bond participates in the transmission of the synergistic effect between the Ni-Fe bimetals. After the carbon nanotubes are doped, the active sites of the catalytic material are fully exposed, and the Ni-Fe bimetals connected by the oxygen bridge can fully exert the synergistic effect between the two.

The invention relates to an alkali metal oxalofluoroborate nonlinear optical crystal, a preparation method and application thereof. The crystal has a general chemical formula of M3[B3O3F2(OH)(C2O4)][B3O3F2(OH)2], where M=K or Rb, and has molecular formulas of K3[B3O3F2(OH)(C2O4)][B3O3F2(OH)2] or Rb3[B3O3F2(OH)(C2O4)][B3O3F2(OH)2], respectively. The molecular weights are 632.31 and 493.20, respectively. The crystal is grown by a hydrothermal method or a room temperature solution method. The cutoff edge of the crystal obtained by the method is less than 200 nm. The preparation method of the crystal is simple, the physicochemical properties are stable, and the crystal can be used as a short-wavelength ultraviolet nonlinear optical crystal in an all-solid-state laser.

The invention relates to poly (ethylene glycol terephthalate-co-isosorbide oxalate) and a polymerization method thereof, and belongs to the technical field of high polymer materials. The preparation method of the copolyester comprises the following steps: directly esterifying terephthalic acid and ethylene glycol to synthesize bis (2-hydroxyethyl) terephthalate; carrying out ester exchange on the dimethyl oxalate and isosorbide to synthesize isosorbide oxalate; and carrying out polycondensation to prepare the copolyester high polymer material. The material disclosed by the invention is a repetitive unit consisting of bis (2-hydroxyethyl) terephthalate and isosorbide oxalate, and has the glass transition temperature of higher than 90 DEG C, the intrinsic viscosity of higher than 0.50 dl / g and the impact strength of higher than 4.2 kJ / m < 2 >.

The invention relates to the technical field of genetic engineering, in particular to a regulatory protein related to biosynthesis of secalonic acid from penicillium oxalicum and application of the regulatory protein. The protein comprises an amino acid sequence as shown in any one of SEQ ID NO. 1-3. The coding gene of the protein comprises nucleotide sequences as shown in SEQ ID NO. 1-3. The application comprises the step of regulating and controlling the secalonic acid production level in microorganisms. Three regulatory proteins related to secalonic acid synthesis are obtained through research, and the production level of secalonic acid can be effectively improved through overexpression of the three proteins. The regulatory protein provided by the invention can effectively improve the yield of the anti-tumor active compound secalonic acid D, and has important application value in the field of secalonic acid production.

The invention relates to the technical field of biochemical engineering, in particular to a preparation method of 4-(hydroxymethylphosphonyl)-2-oxobutyric acid, which comprises the following steps: S1) performing Claisen condensation reaction on a compound as shown in a formula I and oxalate as shown in a formula II under the action of an alkaline condensing agent to obtain a metal salt intermediate as shown in a formula III; and S2) contacting the metal salt intermediate shown in the formula III with aqueous acid to neutralize and desalt, and carrying out acidolysis to obtain the 4-(hydroxymethylphosphonyl)-2-oxobutyric acid shown in the formula IV. According to the present invention, the water-containing acid is adopted to remove the salt before the water-containing acid is adopted, after the Claisen condensation reaction is completed, the water-containing acid is added to replace the cations such as sodium ions in the alkaline condensing agent so as to generate the corresponding metal salt, and the metal salt is rapidly separated out in the solvent system, such that the salt forming particle size is effectively controlled, and the salt is easily filtered and removed; and acidizing and hydrolyzing the mother liquor to obtain the product 4-(hydroxymethylphosphonyl)-2-oxobutyric acid. The method has the characteristics of simplicity in operation, low energy consumption and the like.

The application belongs to the technical field of compound preparation, and particularly relates to a preparation method of an alkali metal salt of an oxalate chelate structure, at least comprising the following steps: mixing tris(trimethylsilyl) phosphate, an oxalate and a phosphorus-containing or boron-containing fluorine compound in a first organic solvent, stirring and heating to obtain lithium phosphate, trimethyl fluorosilane gas, and difluorobisoxalate phosphate or difluorooxalate borate, filtering the reaction solution to obtain lithium phosphate solid and a difluorobisoxalate phosphate solution or a difluorooxalate borate solution; adding a second organic solvent for recrystallization after concentration; and obtaining difluorobisoxalate phosphate or difluorooxalate borate solid after filtration, and drying the solid under reduced pressure to obtain a finished product. The process is simple, and the cost is low. By-products lithium phosphate, potassium fluoride and hexamethyldisiloxane can be directly sold as products after purification. Therefore, the application has an atomic utilization rate close to 100%, no invalid waste, less three-waste emissions, and is friendly to the environment.

This disclosure provides a process for preparing α-hydroxy esters by adding a vinyl Grignard reagent to an oxalate ester and then thiolated the resulting double bond. It also provides α-hydroxy esters and synthetic intermediates prepared according to the process disclosed herein, as well as compositions comprising said α-hydroxy esters.

The present application relates to hydrogen peroxide (H2O2) sensitive covalent cyclodextrin framework and its preparation method and application. Specifically, the covalent cyclodextrin framework is a cyclodextrin-metal organic framework with covalently linked peroxymonosulfate groups and / or covalently modified by phenylboronic acid ester cross-linking agent. The covalent cyclodextrin framework of the present application has hydrogen peroxide sensitivity, can reduce the level of hydrogen peroxide, and shows good antioxidant and anti-inflammatory capacity in vivo and in vitro. It can also play a synergistic therapeutic effect with drug molecules. The covalent cyclodextrin framework of the present application also has suitable biodegradability, good biological safety, and also has a large specific surface area for drug loading, and is an excellent drug carrier.

The application relates to the technical field of medicines, and particularly discloses 13C2-alpha-ketoisocaproic acid and a sodium salt thereof, which is prepared by adopting oxalyl dichloride-13C2 as an isotope-labeled raw material, and through three core reactions of low-temperature nucleophilic addition, room-temperature hydrolysis into a salt and acidification refining, and combining with a recrystallization and reduced-pressure distillation purification process to obtain high-purity 13C2-alpha-ketoisocaproic acid sodium salt and 13C2-alpha-ketoisocaproic acid. The synthesis route is short, the reaction condition is mild and controllable, general industrial raw materials are adopted, and large-scale industrial production can be realized; meanwhile, the 13C2 labeling site is introduced, the isotope atom utilization rate is high, the isotope synthesis cost is effectively reduced, high-purity and high-yield products are finally prepared, the batch stability is excellent, the high-end reagent use demand of clinical 13C breath test for evaluating liver mitochondrial function can be completely met, and the application has a wide application prospect.

The invention provides a recombinant algal strain for expressing glycollic acid oxidase, catalase and oxalate oxidase as well as a construction method and application of the recombinant algal strain, and belongs to the technical field of genetic engineering. The invention provides a recombinant microalgae strain, which is a microalgae strain for expressing glycollic acid oxidase, catalase and oxalate oxidase in chloroplast. The recombinant microalgae strain can decompose a light respiration by-product glycollic acid into carbon dioxide, the carbon dioxide concentration of chloroplast is improved, the carbon sequestration efficiency of microalgae is effectively improved, and fixed CO2 can be converted into biomass, glucose, cane sugar, starch, grease and other metabolites and bioactive substances. The recombinant microalgae strain disclosed by the invention has a wide application prospect in the aspects of biological carbon sequestration, synthesis of microalgae metabolites and preparation of microalgae bioactive substances.

The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formulaand pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

The invention discloses a novel pregabalin eutectic and a preparation method thereof. The eutectic is composed of a pregabalin-cinnamic acid (1: 1) eutectic, a pregabalin-vanillic acid (2: 1) eutectic and a pregabalin-p-toluic acid (1: 1) eutectic. The preparation method comprises multi-step solvent mediated crystallization, and high-purity (more than or equal to 99.5%) and high-yield (more than or equal to 75%) preparation of the eutectic is realized by optimizing an ethyl acetate-ethanol-water solvent system, a reaction temperature (60 DEG C) and inert gas protection conditions. In an accelerated stability test, the increase amount of the content of related substances in the obtained co-crystal within 6 months is less than or equal to 0.3%, the relative bioavailability in a Beagle model reaches 2.2 times of that of a commercially available preparation, the plasma concentration peak value (Cmax) is improved by 1.8-2.5 times, and the half-life period (t1 / 2) is prolonged to 5-7 hours. The method is mild in process condition and low in solvent residue, the clinical curative effect and medication safety of pregabalin are remarkably improved, and the method has a wide industrial application prospect.

The invention relates to the technical field of lithium ion batteries, and discloses a composition for an electrolyte, the electrolyte as well as a preparation method and application of the electrolyte. The composition contains a lithium salt, a solvent, a film-forming additive and a composite additive, based on the total mass of the composition, the content of the lithium salt is 9.5-15 wt%, the content of the solvent is 65-90 wt%, the content of the film-forming additive is 2-5 wt%, and the content of the composite additive is 0.1-3 wt%. The composite additive is a combination of lithium phosphate difluoro bis (oxalate) and 2, 6-difluoronicotinonitrile in a content mass ratio of 1: (0.55-1.8). After the electrolyte provided by the invention is applied to a battery, the interface impedance of a negative electrode can be remarkably reduced, the interface stability of a single-particle graphite negative electrode is improved, the rate capability and the cycle performance of the battery are improved, meanwhile, the oxidation resistance of the electrolyte can be improved, the oxygenolysis of the electrolyte in long-term operation is slowed down, and the dissolution of transition metal of a positive electrode is inhibited.

The invention relates to a chiral synthesis method of an S-citalopram intermediate, and belongs to the technical field of raw material medicine synthesis. The invention aims to overcome the defects in the prior art and provides a chiral synthesis method of a citalopram intermediate compound 3 so as to improve the resolution yield and reduce the production cost of raw material medicines. According to the present invention, the chiral reagent is utilized to induce the addition step of the Grignard reagent, the obtained compound 3 mainly comprises the S configuration, and the subsequent D-di-p-toluoyl tartaric acid resolution is performed so as to improve the S citalopram yield. According to the present invention, the chiral boron reagent is adopted to induce, such that the resolution efficiency is improved, and the cost of the escitalopram oxalate production process is reduced.